Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13046-018-0804-5 http://scihub22266oqcxt.onion/10.1186/s13046-018-0804-5 C6029357!6029357!29970138     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Clin+Cancer+Res 2018 ; 37 (ä): ä Nephropedia Template TP {{tp|p=29970138|t=2018. 17?-estradiol upregulates IL6 expression through the ER? pathway to promote lung adenocarcinoma progression |pdf=|usr=}}{{29970138}} gab.com Text 17 -estradiol upregulates IL6 expression through the ER pathway to promote lung adenocarcinoma progression JO: J Exp Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=29970138 #FOAvip Background: In non-small cell lung cancer (NSCLC), estrogen (E2) significantly promotes NSCLC cell growth via estrogen receptor beta (ER?). Discovery and elucidation of the mechanism underlying estrogen-promoted NSCLC progression is critical for effective preventive interventions. IL6 has been demonstrated to be involved in the development, progression and metastasis in several cancers and IL6 overexpression is associated with poor prognosis in NSCLC. However, the exact role played by IL6 in estrogen-promoted NSCLC progress remain unknown. Here, we evaluated the expression and biological effects of IL6 in NSCLC cells when treated with E2 and explored the underlying mechanism of IL6 in E2-promoted NSCLC progression. Methods: Expression of ER?/IL6 in 289 lung cancer samples was assessed by immunohistochemistry. Matched samples of metastatic lymph node and primary tumor tissues were used to quantify the expression of ER?/IL6 by western blot. Expression levels of IL6 in NSCLC cells were quantified by western blotting, ELISA, and immunofluorescence staining. The effects of IL6 stimulated by E2 on cell malignancy were evaluated using CCK8, colony formation, wound healing and transwell. Furthermore, overexpression and knockdown ER? constructs were constructed to measure the expression of IL6. The effects of IL6 stimulated by E2 on tumor growth were evaluated using a urethane-induced adenocarcinoma model. In addition, a xenograft mouse model was used to observe differences in ER? subtype tumor growth with respect to IL6 expression. Results: IL6/ER? expression were significantly increased in lung cancer. Higher IL6/ER? expression was associated with decreased differentiation or increased metastasis. IL6 was an independent prognostic factor for overall survival (OS), higher IL6 expression was associated with decreased OS. Furthermore, ER? regulates IL6 expression via MAPK/ERK and PI3K/AKT pathways when stimulated by E2 and promotes cell malignancy in vitro and induced tumor growth in vivo. Finally we confirm that ER? isolation 1/5 is essential for E2 promotion of IL6 expression, while ER?2 not. Conclusions: Our findings demonstrate that E2 stimulates IL6 expression to promote lung adenocarcinoma progression through the ER? pathway. We also clarify the difference in each ER? subtype for E2 promoting IL6 expression, suggesting that ER?/IL6 might be potential targets for prognostic assessment and therapeutic intervention in lung cancer. Electronic supplementary material: The online version of this article (10.1186/s13046-018-0804-5) contains supplementary material, which is available to authorized users. Twit Text FOAVip 17 -estradiol upregulates IL6 expression through the ER pathway to promote lung adenocarcinoma progression ????J Exp Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=29970138 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29970138 #FOAvip English Wikipedia <ref>{{Cite pmid|29970138}}</ref> 17?-estradiol upregulates IL6 expression through the ER? pathway to promote lung adenocarcinoma progression #MMPMID29970138 Huang Q; Zhang Z; Liao Y; Liu C; Fan S; Wei X; Ai B; Xiong J J Exp Clin Cancer Res 2018[]; 37 (ä): ä PMID29970138show ga Background: In non-small cell lung cancer (NSCLC), estrogen (E2) significantly promotes NSCLC cell growth via estrogen receptor beta (ER?). Discovery and elucidation of the mechanism underlying estrogen-promoted NSCLC progression is critical for effective preventive interventions. IL6 has been demonstrated to be involved in the development, progression and metastasis in several cancers and IL6 overexpression is associated with poor prognosis in NSCLC. However, the exact role played by IL6 in estrogen-promoted NSCLC progress remain unknown. Here, we evaluated the expression and biological effects of IL6 in NSCLC cells when treated with E2 and explored the underlying mechanism of IL6 in E2-promoted NSCLC progression. Methods: Expression of ER?/IL6 in 289 lung cancer samples was assessed by immunohistochemistry. Matched samples of metastatic lymph node and primary tumor tissues were used to quantify the expression of ER?/IL6 by western blot. Expression levels of IL6 in NSCLC cells were quantified by western blotting, ELISA, and immunofluorescence staining. The effects of IL6 stimulated by E2 on cell malignancy were evaluated using CCK8, colony formation, wound healing and transwell. Furthermore, overexpression and knockdown ER? constructs were constructed to measure the expression of IL6. The effects of IL6 stimulated by E2 on tumor growth were evaluated using a urethane-induced adenocarcinoma model. In addition, a xenograft mouse model was used to observe differences in ER? subtype tumor growth with respect to IL6 expression. Results: IL6/ER? expression were significantly increased in lung cancer. Higher IL6/ER? expression was associated with decreased differentiation or increased metastasis. IL6 was an independent prognostic factor for overall survival (OS), higher IL6 expression was associated with decreased OS. Furthermore, ER? regulates IL6 expression via MAPK/ERK and PI3K/AKT pathways when stimulated by E2 and promotes cell malignancy in vitro and induced tumor growth in vivo. Finally we confirm that ER? isolation 1/5 is essential for E2 promotion of IL6 expression, while ER?2 not. Conclusions: Our findings demonstrate that E2 stimulates IL6 expression to promote lung adenocarcinoma progression through the ER? pathway. We also clarify the difference in each ER? subtype for E2 promoting IL6 expression, suggesting that ER?/IL6 might be potential targets for prognostic assessment and therapeutic intervention in lung cancer. Electronic supplementary material: The online version of this article (10.1186/s13046-018-0804-5) contains supplementary material, which is available to authorized users. ä17?-estradiol upregulates IL6 expression through the ER? pathway to pr(epmc).pdf DeepDyve Pubget Overpricing